Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cyclophosphamide + total body irradiation
- Development stage
- Phase 3
- Lead developer
- Center for International Blood and Marrow Transplant Research
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Conditioning Regimen E is a specific preparative regimen used in the context of hematopoietic stem cell transplantation (HSCT), specifically evaluated in the CIBMTR ACCELERATE platform trial. It consists of a combination of the chemotherapy agents fludarabine and cyclophosphamide, along with low-dose total body irradiation (TBI). Fludarabine is a purine antimetabolite that interferes with DNA synthesis, while cyclophosphamide is an alkylating agent that cross-links DNA. The addition of TBI provides further myeloablation and potent immunosuppression to facilitate donor engraftment and reduce the risk of graft rejection. This regimen is designed to prepare patients with hematologic malignancies for mismatched unrelated donor (MMUD) peripheral blood stem cell transplantation, often used in conjunction with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis.
- Other names
- Fludarabine/cyclophosphamide/total body irradiationFlu/Cy/TBI regimen
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + cyclophosphamide + total body irradiation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cyclophosphamide + total body irradiation.